Cargando…

Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience

In aggressive pituitary tumors (PT) showing local invasion or growth/recurrence despite multimodal conventional treatment, temozolomide (TMZ) is considered a further therapeutic option, while little data are available on peptide receptor radionuclide therapy (PRRT). We analyzed PRRT effectiveness, s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giuffrida, G, Ferraù, F, Laudicella, R, Cotta, O R, Messina, E, Granata, F, Angileri, F F, Vento, A, Alibrandi, A, Baldari, S, Cannavò, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499924/ https://www.ncbi.nlm.nih.gov/pubmed/30939449 http://dx.doi.org/10.1530/EC-19-0065

Ejemplares similares

Epidemiology, course, and outcomes of Sars-CoV-2 infection in patients with acromegaly and Cushing’s disease: a monocentric experience in Southern Italy
por: Ragonese, M., et al.
Publicado: (2023)

Multidisciplinary Management of Pituitary Apoplexy
por: Albani, Adriana, et al.
Publicado: (2016)

Shrinkage of a pituitary metastasis of melanoma induced by pembrolizumab: a case report
por: Giuffrida, Giuseppe, et al.
Publicado: (2021)

Methylome Analysis in Nonfunctioning and GH-Secreting Pituitary Adenomas
por: Giuffrida, Giuseppe, et al.
Publicado: (2022)

The Effects of Peptide Receptor Radionuclide Therapy on the Neoplastic and Normal Pituitary
por: Marques, Pedro
Publicado: (2023)

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
por: Elston, Marianne S., et al.
Publicado: (2021)

Synergism of Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy in the Treatment of Pituitary Carcinoma
por: Lin, Andrew L, et al.
Publicado: (2021)

Serum NT-pro-BNP Levels Predict Cardiovascular Events in Acromegaly Patients
por: Ragonese, Marta, et al.
Publicado: (2021)

Temozolomide-Induced Shrinkage of a Pituitary Carcinoma Causing Cushing's Disease — Report of a Case and Literature Review
por: Curtò, Lorenzo, et al.
Publicado: (2010)

Peptide Receptor Radionuclide Therapy
por: Hofland, Johannes, et al.
Publicado: (2022)

What we have to know about corticosteroids use during Sars-Cov-2 infection
por: Ferraù, F., et al.
Publicado: (2020)

Undetectable or low (<1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients
por: Campennì, Alfredo, et al.
Publicado: (2018)

Peptide Receptor Radionuclide Therapy in Thyroid Cancer
por: Gubbi, Sriram, et al.
Publicado: (2022)

Somatic Deletion in Exon 10 of Aryl Hydrocarbon Receptor Gene in Human GH-Secreting Pituitary Tumors
por: Re, Agnese, et al.
Publicado: (2020)

Immunohistochemical localization and functional characterization of somatostatin receptor subtypes in a corticotropin releasing hormone-secreting adrenal phaeochromocytoma: review of the literature and report of a case
por: Ruggeri, R.M., et al.
Publicado: (2009)

SUN-274 Pituitary Macroadenoma Treated with Peptide Receptor Radionuclide Therapy in a Patient with Common Variable Immunodeficiency - Case Report
por: Brodowska-Kania, Dorota, et al.
Publicado: (2020)

Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls
por: Beukhof, Carolien M., et al.
Publicado: (2019)

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
por: da Silva, Tiago Nunes, et al.
Publicado: (2018)

COVID-19 in Italian Sjögren's syndrome patients: a monocentric study
por: Giardina, F., et al.
Publicado: (2020)

The Current Role of Peptide Receptor Radionuclide Therapy in Meningiomas
por: Fodi, Christina-Katharina, et al.
Publicado: (2022)

Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements
por: Merola, Elettra, et al.
Publicado: (2023)

Improved Quality of Life in Patients Treated with Peptide Radionuclides
por: Traub-Weidinger, T, et al.
Publicado: (2011)

Surgical treatment of aggressive pituitary adenomas and pituitary carcinomas
por: Buchfelder, Michael, et al.
Publicado: (2020)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
por: Nonnekens, Julie, et al.
Publicado: (2016)

Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor
por: Häfliger, Simon, et al.
Publicado: (2020)

Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview
por: Cimini, Andrea, et al.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward
por: Feijtel, Danny, et al.
Publicado: (2020)

Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment
por: Burman, Pia, et al.
Publicado: (2023)

Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies
por: Bison, Sander M., et al.
Publicado: (2015)

Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights
por: Starr, Jason S, et al.
Publicado: (2020)

Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics
por: Chakraborty, Kushal, et al.
Publicado: (2023)

Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors
por: Pusceddu, Sara, et al.
Publicado: (2022)

Temozolomide in aggressive pituitary adenomas and carcinomas
por: Ortiz, Leon D., et al.
Publicado: (2012)

Selective Radionuclide Localisation in Primary Liver Tumours
por: Novell, J. R., et al.
Publicado: (1994)

Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2014)

Lymphocytic Hypophysitis: Differential Diagnosis and Effects of High-Dose Pulse Steroids, Followed by Azathioprine, on the Pituitary Mass and Endocrine Abnormalities — Report of a Case and Literature Review
por: Curtò, Lorenzo, et al.
Publicado: (2010)

In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib
por: Feijtel, Danny, et al.
Publicado: (2023)

Peptide Receptor Radionuclide Therapy of Differentiated Thyroid Cancer: Efficacy and Toxicity
por: Czepczyński, Rafał, et al.
Publicado: (2014)

Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours
por: Lim, Lisi Elizabeth, et al.
Publicado: (2020)

Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy
por: Minczeles, N.S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6br966e1vgtr6hsm3cvmj9tlvm